Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butanal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butanal SCHEMBL28436922 | 1.00 | — | — | |
| Butanal SCHEMBL4668402 | 1.00 | — | — | |
| Butanal SCHEMBL9303364 | 0.96 | ALDH1A1 (1.00) | — | |
| Butanal SCHEMBL7323870 | 0.96 | — | — | |
| Butanal SCHEMBL807 | 0.96 | — | — | |
| Butanal SCHEMBL597713 | 0.96 | ALDH1A1 (1.00) | — | |
| Butanal SCHEMBL23854344 | 0.92 | — | — | |
| Butanal SCHEMBL2049306 | 0.92 | — | — | |
| Butanal SCHEMBL14973385 | 0.92 | — | — | |
| Butanal SCHEMBL21142995 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038910-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119630392-A | Phospholipid compositions comprising EPA and/or DHA for improving neurodegenerative and age-related neurodegenerative disorders | 阿克海洋生物人类原料公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025038910-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112867721-B | STING agonistic compounds | 小野药品工业株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-108689879-B | Process for synthesizing 2-cyanoethyl-5-noramylene-2-aldehyde | 山东汇盟生物科技股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-110099697-A | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | 诺华股份有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-105189446-B | Phloroglucin analog derivative and its purposes in treating neurodegenerative disease | 中国医学科学院药物研究所 | 2018-07-20 | — | — | CN | disclosed |
| CN-105189446-A | Phloroglucinol derivatives and application thereof in treatment of neurodegenerative disorder | INST MATERIA MEDICA CAMS | 2015-12-23 | — | — | CN | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| CN-101641360-A | Piperazine derivatives, preparation method and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-5114966-A | Radical scavengers | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1992-05-19 | — | — | US | disclosed |
| EP-0413668-A2 | New 2,3-dihydro-5-oxy-4,6,7-trimethylbenzofuranes 2-(RS)-substitutes, useful as antioxidizing pharmaceutical products having mucoregolating and anti-ischemic properties | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1991-02-20 | — | — | EP | disclosed |